Caroline J Voskens Simone M Goldinger Carmen Loquai Caroline Robert Katharina C Kaehler Carola Berking Tanja Bergmann Clemens L Bockmeyer Thomas Eigentler Michael Fluck Claus Garbe Ralf Gutzmer Stephan Grabbe Axel Hauschild Rüdiger Hein Gheorghe Hundorfean Armin Justich Ullrich Keller Christina Klein Christine Mateus Peter Mohr Sylvie Paetzold Imke Satzger Dirk Schadendorf Marc Schlaeppi Gerold Schuler Beatrice Schuler-Thurner Uwe Trefzer Jens Ulrich Julia Vaubel Roger von Moos Patrik Weder Tabea Wilhelm Daniela Göppner Reinhard Dummer Lucie M Heinzerling
10.1371/journal.pone.0053745
PLoS One
2013;8(1):e53745.
CC BY
https://pubmed.ncbi.nlm.nih.gov/23341990/
Antibodies, Monoclonal / adverse effects Antibodies, Monoclonal / immunology CTLA-4 Antigen / immunology Melanoma / drug therapy Melanoma / pathology Skin Neoplasms / drug therapy
Antibodies, Monoclonal / adverse effects Antibodies, Monoclonal / immunology CTLA-4 Antigen / immunology Melanoma / drug therapy Melanoma / pathology Skin Neoplasms / drug therapy Case Reports Adult Aged Aged, 80 and over Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / adverse effects Antineoplastic Agents / immunology Antineoplastic Agents / therapeutic use Endocrine System / drug effects Female Gastrointestinal Tract / drug effects Humans Ipilimumab Kidney / drug effects Liver / drug effects Male Middle Aged Neoplasm Metastasis Nervous System / drug effects Pancreas / drug effects Respiratory System / drug effects Retrospective Studies Skin / drug effects Antibodies, Monoclonal Antineoplastic Agents CTLA-4 Antigen Ipilimumab
PMC3544906
23341990
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
2013